# Travere Therapeutics, Inc.: overview

TVTX · Nasdaq · CIK 1438533 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tvtx.md) · [Financials](/companies/tvtx/financials.md) · [Filings](/companies/tvtx/filings.md) · [Insiders](/companies/tvtx/insiders.md)

Latest reported revenue: [$169.6m](/filings/0001438533-26-000063.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001438533-26-000063).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [62.9](/filings/0001438533-25-000056.md) | [74.8 d](/filings/0001438533-26-000014.md) | [81.7](/filings/0001438533-26-000042.md) | [114](/filings/0001438533-26-000063.md) | [165](/filings/0001438533-25-000056.md) | [130 d](/filings/0001438533-26-000014.md) | [127](/filings/0001438533-26-000042.md) | [170](/filings/0001438533-26-000063.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(89.3%)](/filings/0001438533-25-000056.md) | [(81.2%) d](/filings/0001438533-26-000014.md) | [(52.2%)](/filings/0001438533-26-000042.md) | [(11.1%)](/filings/0001438533-26-000063.md) | [15.1%](/filings/0001438533-25-000056.md) | [(25.0%) d](/filings/0001438533-26-000014.md) | [(29.0%)](/filings/0001438533-26-000042.md) | [2.3%](/filings/0001438533-26-000063.md) |
| Net margin | % | [(87.1%)](/filings/0001438533-25-000056.md) | [(80.6%) d](/filings/0001438533-26-000014.md) | [(50.4%)](/filings/0001438533-26-000042.md) | [(11.1%)](/filings/0001438533-26-000063.md) | [15.6%](/filings/0001438533-25-000056.md) | [2.1% d](/filings/0001438533-26-000014.md) | [(29.2%)](/filings/0001438533-26-000042.md) | [(20.5%)](/filings/0001438533-26-000063.md) |
| Diluted EPS | $ per share | [(0.70)](/filings/0001438533-25-000056.md) | not reported | [(0.47)](/filings/0001438533-26-000042.md) | [(0.14)](/filings/0001438533-26-000063.md) | [0.28](/filings/0001438533-25-000056.md) | not reported | [(0.40)](/filings/0001438533-26-000042.md) | [(0.37)](/filings/0001438533-26-000063.md) |
| Free cash flow | $m | [(42.5) d](/filings/0001438533-25-000056.md) | not reported | not reported | not reported | [14.2 d](/filings/0001438533-25-000056.md) | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [132](/filings/0001438533-24-000005.md) | [109](/filings/0001438533-25-000010.md) | [145](/filings/0001438533-26-000014.md) | [233](/filings/0001438533-26-000014.md) | [491](/filings/0001438533-26-000014.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(151.3%)](/filings/0001438533-24-000005.md) | [(292.2%)](/filings/0001438533-25-000010.md) | [(267.2%)](/filings/0001438533-26-000014.md) | [(138.9%)](/filings/0001438533-26-000014.md) | [(12.8%)](/filings/0001438533-26-000014.md) |
| Net margin | % | [(136.6%)](/filings/0001438533-24-000005.md) | [(254.4%)](/filings/0001438533-25-000010.md) | [(76.7%)](/filings/0001438533-26-000014.md) | [(137.9%)](/filings/0001438533-26-000014.md) | [(5.2%)](/filings/0001438533-26-000014.md) |
| Diluted EPS | $ per share | [(3.01)](/filings/0001438533-24-000005.md) | [(4.37)](/filings/0001438533-25-000010.md) | [(1.50)](/filings/0001438533-26-000014.md) | [(4.08)](/filings/0001438533-26-000014.md) | [(0.29)](/filings/0001438533-26-000014.md) |
| Free cash flow | $m | [(19.9)](/filings/0001438533-24-000005.md) | [(186)](/filings/0001438533-25-000010.md) | [(281)](/filings/0001438533-26-000014.md) | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tvtx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $643.3m | 11,324,191 |  | Not compared |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $455.7m | 8,020,663 |  | Added +228,630 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $403.2m | 7,096,614 |  | Reduced −3,871,353 |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $339.2m | 11,419,586 |  | Not compared |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $259.5m | 4,568,341 |  | Added +3,223,230 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $241.8m | 4,256,224 |  | Reduced −703,764 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $233.4m | 4,108,694 |  | Added +62,882 |
| [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $213.2m | 3,752,574 |  | Reduced −389,977 |
| [NOMURA ASSET MANAGEMENT INTERNATIONAL INC.](/funds/921739.md) | 2026-06-30 | $159.8m | 2,812,514 |  | Reduced −457,999 |
| [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $146.0m | 2,569,356 |  | Added +1,592,356 |

## Recent filings

[All 1,254 filings](/companies/tvtx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-21 | 20:10 ET | [8-K](/filings/0001438533-26-000068.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001438533-26-000068 |
| 2026-08-04 | 20:45 ET | [10-Q](/filings/0001438533-26-000063.md) | Quarterly report, period 2026-06-30 | 0001438533-26-000063 |
| 2026-08-04 | 20:05 ET | [8-K](/filings/0001438533-26-000062.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-26-000062 |
| 2026-07-09 | 21:10 ET | [8-K](/filings/0001438533-26-000054.md) | 5.02 Departure or appointment of officers or directors | 0001438533-26-000054 |
| 2026-06-16 | 20:34 ET | [8-K](/filings/0001438533-26-000048.md) | 5.02 Departure or appointment of officers or directors | 0001438533-26-000048 |
| 2026-06-02 | 11:05 ET | [8-K](/filings/0001193125-26-252474.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-252474 |
| 2026-05-21 | 20:07 ET | [8-K](/filings/0001438533-26-000046.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001438533-26-000046 |
| 2026-05-11 | 21:10 ET | [8-K](/filings/0001193125-26-217100.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-217100 |
| 2026-05-04 | 20:45 ET | [10-Q](/filings/0001438533-26-000042.md) | Quarterly report, period 2026-03-31 | 0001438533-26-000042 |
| 2026-05-04 | 20:05 ET | [8-K](/filings/0001438533-26-000041.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-26-000041 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001438533-26-000014.md), filed Feb 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/6f3d4ec6-6cdb-4d47-ac46-3e4d20c28cd0)

## About the filer

- CIK: 1438533
- Tickers: TVTX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: CA
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.